Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Moxisylyte. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxisylyte SCHEMBL317080 | 0.99 | SMN1; SMN2 (1.00) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| Moxisylyte SCHEMBL1649830 | 0.97 | ADRA1D (0.95) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| Moxisylyte SCHEMBL6398989 | 0.94 | ADRA1D (0.88) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| Iproxamine SCHEMBL1815834 | 0.86 | ADRA1D (0.76) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| Iproxamine SCHEMBL120331 | 0.85 | SMN1; SMN2 (0.76) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| SCHEMBL5235884 | 0.84 | ADRA1D (0.72) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| SCHEMBL8924260 | 0.84 | CYP1A2 (0.72) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| SCHEMBL12013918 | 0.84 | CYP1A2 (0.72) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| SCHEMBL4696868 | 0.83 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A | |
| SCHEMBL4695767 | 0.83 | ADRA1D (0.71) | ADRA1DADRA1AADRA1BCYP1A2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1755 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222008-A1 | EYEDROPS CONTAINING AN ALPHA1-BLOCKER FOR INHIBITING MYOPIA PROGRESSION | TSUBOTA LABORATORY, INC. (JP) | 2025-07-10 | — | — | US | claimed |
| EP-4582103-A1 | alpha1 BLOCKER-CONTAINING EYEDROPS FOR INHIBITING MYOPIA PROGRESSION | Tsubota Laboratory, Inc. (JP) | 2025-07-09 | — | — | EP | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| US-12102628-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation | 2024-10-01 | — | — | US | claimed |
| US-20240294986-A1 | PRECISION MEDICINE FOR SCHIZOPHRENIA AND PSYCHOTIC DISORDERS: OBJECTIVE ASSESSMENT, RISK PREDICTION, PHARMACOGENOMICS, AND REPURPOSED DRUGS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2024-09-05 | — | — | US | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| EP-0714300-A1 | METHODS FOR MODULATING THE HUMAN SEXUAL RESPONSE | ZONAGEN, INC. (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0694300-A1 | Treatment of impotence | INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOGIQUES APPLIQUEES (IRCEBA) (FR) | 1996-01-31 | — | — | EP | claimed |
| US-5451609-A | DEACETLY MOXISYLYTE | INSTITUT DE RECHERCHES CHIMIQUES ET AL (FR) | 1995-09-19 | — | — | US | claimed |
| WO-1995005172-A1 | METHODS FOR MODULATING THE HUMAN SEXUAL RESPONSE | ZONAGEN, INC. (US) | 1995-02-23 | — | — | WO | claimed |
| US-5182270-A | Inclusion compound with dimethyl-beta-cyclodextrin | IOLAB CORPORATION (US) | 1993-01-26 | — | — | US | claimed |
| EP-0251680-B1 | CONTROLLED RELEASE BIOERODIBLE DRUG DELIVERY SYSTEM | IOLAB, INC (US) | 1992-04-15 | — | — | EP | claimed |
| EP-0251680-A2 | Controlled release bioerodible drug delivery system | IOLAB, INC (US) | 1988-01-07 | — | — | EP | claimed |
| US-4443441-A | Fixation of intraocular lenses | GALIN MILES A | 1984-04-17 | — | — | US | claimed |
| US-4310524-A | TCA Composition and method for rapid onset antidepressant therapy | RICHARDSON-MERRELL, INC. (US) | 1982-01-12 | — | — | US | claimed |
| EP-0031184-A1 | Process for the preparation of 4-(2-(dimethylamino)-ethoxy)-2-methyl-5-(1-methylethyl)-phenol esters and their salts | BLASCHIM S.p.A. (IT) | 1981-07-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102628-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | ADRA1D 99/4885ADRA1A 74/4885ADRA1B 63/4885 |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | ADRA1D 641/4885ADRA1A 644/4885ADRA1B 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.